<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234217</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-0593</org_study_id>
    <secondary_id>R01HL146127</secondary_id>
    <nct_id>NCT04234217</nct_id>
  </id_info>
  <brief_title>Mechanisms of Prediabetic States in Sleep Apnea</brief_title>
  <official_title>Mechanisms of Prediabetic States in Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AdventHealth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand how sleep apnea contributes to the
      development of diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Substantial evidence indicates that obstructive sleep apnea (OSA) is associated with impaired
      glucose metabolism, however, metabolic mechanisms underlying this association remain unclear.
      This mechanistic study will determine systemic and cellular metabolic pathways that
      contribute to impaired glucose metabolism in obstructive sleep apnea (OSA). Understanding of
      how obstructive sleep apnea (OSA) affects glucose metabolism may help identify novel targets
      for risk prediction and/or treatment of metabolic impairments beyond continuous positive
      airway pressure (CPAP). Obstructive sleep apnea (OSA) patients with prediabetes will be
      studied under three in-laboratory conditions in a randomized cross-over design: untreated
      condition (obstructive sleep apnea), treated condition (continuous positive airway pressure),
      untreated but pharmacologically suppressed lipolysis condition (Niacin). The investigator
      will perform whole body and cellular assessments under each study condition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>Untreated, within 4 months of screening</time_frame>
    <description>Endogenous glucose production will be calculated from blood glucose levels measured during infusion of isotope tracers and using validated modeling methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>CPAP, within 4 months of screening</time_frame>
    <description>Endogenous glucose production will be calculated from blood glucose levels measured during infusion of isotope tracers and using validated modeling methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>Niacin, within 4 months of screening</time_frame>
    <description>Endogenous glucose production will be calculated from blood glucose levels measured during infusion of isotope tracers and using validated modeling methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma norepinephrine levels</measure>
    <time_frame>Untreated, within 4 months of screening</time_frame>
    <description>Plasma norepinephrine will be measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma norepinephrine levels</measure>
    <time_frame>CPAP, within 4 months of screening</time_frame>
    <description>Plasma norepinephrine will be measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma norepinephrine levels</measure>
    <time_frame>Niacin, within 4 months of screening</time_frame>
    <description>Plasma norepinephrine will be measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial respiration</measure>
    <time_frame>Untreated, within 4 months of screening</time_frame>
    <description>Mitochondrial respiration will be derived from mitochondrial oxygen consumption rate using specific analytical methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial respiration</measure>
    <time_frame>CPAP, within 4 months of screening</time_frame>
    <description>Mitochondrial respiration will be derived from mitochondrial oxygen consumption rate using specific analytical methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial respiration</measure>
    <time_frame>Niacin, within 4 months of screening</time_frame>
    <description>Mitochondrial respiration will be derived from mitochondrial oxygen consumption rate using specific analytical methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free fatty acid levels</measure>
    <time_frame>Untreated, within 4 months of screening</time_frame>
    <description>Plasma free fatty acid levels will be measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free fatty acid levels</measure>
    <time_frame>CPAP, within 4 months of screening</time_frame>
    <description>Plasma free fatty acid levels will be measured in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma free fatty acid levels</measure>
    <time_frame>Niacin, within 4 months of screening</time_frame>
    <description>Plasma free fatty acid levels will be measured in blood</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>Untreated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated condition (obstructive sleep apnea)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous positive airway pressure (CPAP) treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous positive airway pressure (CPAP) treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Untreated, pharmacological suppression of lipolysis by Niacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airway pressure</intervention_name>
    <description>Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)</description>
    <arm_group_label>Continuous positive airway pressure (CPAP) treatment</arm_group_label>
    <other_name>CPAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Niacin</intervention_name>
    <description>Suppression of lipolysis by niacin infusion</description>
    <arm_group_label>Niacin</arm_group_label>
    <other_name>Suppression of lipolysis by niacin infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight or obese

          -  Prediabetic

          -  Sleep apnea

        Exclusion Criteria:

          -  Diabetic

          -  Severe hypertension

          -  Taking medications that can confound assessments

          -  Any history of known bleeding disorders

          -  Any underlying disease likely to limit life span or increase risk of intervention

          -  Currently pregnant, trying to get pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esra Tasali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Becky Tucker, BA</last_name>
    <phone>773-702-2348</phone>
    <email>sleepstudy@uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Esra Tasali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

